Skip to main content


Immunotherapy Biomarkers

Section edited by Ignacio Melero, PhD

Consisting of predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty.

Page 1 of 2

  1. Content type: Research article

    Immune checkpoint inhibitors (ICIs) have achieved impressive success in different cancer types, yet responses vary and predictive biomarkers are urgently needed. Growing evidence points to a link between DNA m...

    Authors: Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang and Rui-Hua Xu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:264

    Published on:

  2. Content type: Research article

    Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with an overall 5-year survival rate of less than 8%. New evidence indicates that PDAC cells release pro-inflammatory metabolites that in...

    Authors: Rosalinda Trovato, Alessandra Fiore, Sara Sartori, Stefania Canè, Rosalba Giugno, Luciano Cascione, Salvatore Paiella, Roberto Salvia, Francesco De Sanctis, Ornella Poffe, Cristina Anselmi, Francesca Hofer, Silvia Sartoris, Geny Piro, Carmine Carbone, Vincenzo Corbo…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:255

    Published on:

  3. Content type: Research article

    In melanoma, there is no companion diagnostic test to predict response to programmed cell death 1 (PD-1) axis immune checkpoint inhibitor (ICI) therapy. In the adjuvant setting, only one in five patients may b...

    Authors: Swati Gupta, Leena McCann, Yvonne G. Y. Chan, Edwin W. Lai, Wei Wei, Pok Fai Wong, James W. Smithy, Jodi Weidler, Brian Rhees, Michael Bates, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:254

    Published on:

  4. Content type: Research article

    There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequenc...

    Authors: Michael Fehlings, Suchit Jhunjhunwala, Marcin Kowanetz, William E. O’Gorman, Priti S. Hegde, Hermi Sumatoh, Boon Heng Lee, Alessandra Nardin, Etienne Becht, Susan Flynn, Marcus Ballinger, Evan W. Newell and Mahesh Yadav

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:249

    Published on:

  5. Content type: Research article

    Programmed cell death protein 1 (PD-1) is a key immune checkpoint that regulates peripheral tolerance and protects against autoimmunity. Programmed death ligand-2 (PD-L2) is a less studied ligand to PD-1 and h...

    Authors: Yiyin Zhang, Jin Xu, Jie Hua, Jiang Liu, Chen Liang, Qingcai Meng, Miaoyan Wei, Bo Zhang, Xianjun Yu and Si Shi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:233

    Published on:

  6. Content type: Research article

    Myeloid-derived suppressor cells (MDSC) have been found to play an important role in limiting immune responses in cancer. Higher circulating MDSC levels have been associated with greater tumor burden, poorer r...

    Authors: Minjun C. Apodaca, Amy E. Wright, Angela M. Riggins, William P. Harris, Raymond S. Yeung, Lei Yu and Chihiro Morishima

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:230

    Published on:

  7. Content type: Research article

    A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical a...

    Authors: Zi-Qi Zhou, Jing-Jing Zhao, Qiu-Zhong Pan, Chang-Long Chen, Yuan Liu, Yan Tang, Qian Zhu, De-Sheng Weng and Jian-Chuan Xia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:228

    Published on:

  8. Content type: Short report

    Despite major improvements in combatting metastatic melanoma since the advent of immunotherapy, the overall survival for patients with advanced disease remains low. Recently, there is a growing number of repor...

    Authors: Douglas Donnelly, Shirin Bajaj, Jaehong Yu, Miles Hsu, Arjun Balar, Anna Pavlick, Jeffrey Weber, Iman Osman and Judy Zhong

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:222

    Published on:

  9. Content type: Research article

    To profile genomic and epigenomic of a naïve Chinese non-small cell lung cancer (NSCLC) cohort and investigate the association between tumor mutation burden (TMB) and DNA methylation (DNAm) to explore potentia...

    Authors: Liangliang Cai, Hua Bai, Jianchun Duan, Zhijie Wang, Shugeng Gao, Di Wang, Shuhang Wang, Jun Jiang, Jiefei Han, Yanhua Tian, Xue Zhang, Hao Ye, Minghui Li, Bingding Huang, Jie He and Jie Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:198

    Published on:

  10. Content type: Research article

    The cancer-associated fibroblast (CAF) population is implicated in immune dysregulation. Here, we test the hypothesis that CAF profiles in pretreatment tumor specimens are associated with response to immune ch...

    Authors: Pok Fai Wong, Wei Wei, Swati Gupta, James W. Smithy, Daniel Zelterman, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:194

    Published on:

  11. Content type: Short report

    Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the res...

    Authors: Yi Zheng, Tingting Wang, Xiaoxuan Tu, Yun Huang, Hangyu Zhang, Di Tan, Weiqin Jiang, Shunfeng Cai, Peng Zhao, Ruixue Song, Peilu Li, Nan Qin and Weijia Fang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:193

    Published on:

  12. Content type: Research article

    Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the patients do not respond to these treatments and...

    Authors: Andrea Forschner, Florian Battke, Dirk Hadaschik, Martin Schulze, Stephanie Weißgraeber, Chung-Ting Han, Maria Kopp, Maximilian Frick, Bernhard Klumpp, Nicola Tietze, Teresa Amaral, Peter Martus, Tobias Sinnberg, Thomas Eigentler, Ulrike Keim, Claus Garbe…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:180

    Published on:

  13. Content type: Research article

    Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citr...

    Authors: Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet and Etienne Giroux Leprieur

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:176

    Published on:

  14. Content type: Short report

    Immune checkpoint pathways active in Acute Myeloid Leukemia (AML) patients, especially during the course of remission induction chemotherapy, have not been well studied. Although dominant in mediating T cell d...

    Authors: Paola Dama, Marshall Tang, Noreen Fulton, Justin Kline and Hongtao Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:175

    Published on:

  15. Content type: Research article

    Non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitors show long lasting responses, but it is hard to predict which patients will profit from this treatment with the currently used mark...

    Authors: Menno Tamminga, Sanne de Wit, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Leon W. M. M. Terstappen and Harry J. M. Groen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:173

    Published on:

  16. Content type: Short report

    Tumor-associated macrophages have been well-characterized in solid malignancies, including renal cell carcinoma and generally correlate with poor prognosis. However, the molecular mechanisms which govern intra...

    Authors: Jason B. Muhitch, Nicholas C. Hoffend, Gissou Azabdaftari, Austin Miller, Wiam Bshara, Carl D. Morrison, Thomas Schwaab and Scott I. Abrams

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:155

    Published on:

  17. Content type: Research article

    Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for mark...

    Authors: Andre Kunert, Edwin A. Basak, Daan P. Hurkmans, Hayri E. Balcioglu, Yarne Klaver, Mandy van Brakel, Astrid A. M. Oostvogels, Cor H. J. Lamers, Sander Bins, Stijn L. W. Koolen, Astrid A. M. van der Veldt, Stefan Sleijfer, Ron H. J. Mathijssen, Joachim G. J. V. Aerts and Reno Debets

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:149

    Published on:

  18. Content type: Research article

    Molecular subtyping of urothelial cancer (UC) has significantly advanced the understanding of bladder tumor heterogeneity and development of prognostic and predictive biomarkers. Evolving evidence across cance...

    Authors: Thiago Vidotto, Sarah Nersesian, Charles Graham, D. Robert Siemens and Madhuri Koti

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:148

    Published on:

  19. Content type: Short report

    The progression of cancer requires mutational adaptation to permit unrestrained proliferation. A fraction of cancer mutations are oncogenic drivers, while others are putative ‘passengers’ that do not contribut...

    Authors: Yu Wang, Douglas B. Johnson, Steve Lu, Luis A. Diaz Jr, Yaomin Xu and Justin M. Balko

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:123

    Published on:

  20. Content type: Research article

    Immune checkpoint therapies (ICTs) targeting the programmed cell death-1 (PD1)/programmed cell death ligand-1 (PD-L1) pathway have improved outcomes for patients with non-small cell lung cancer (NSCLC), partic...

    Authors: Sonja Althammer, Tze Heng Tan, Andreas Spitzmüller, Lorenz Rognoni, Tobias Wiestler, Thomas Herz, Moritz Widmaier, Marlon C. Rebelatto, Helene Kaplon, Diane Damotte, Marco Alifano, Scott A. Hammond, Marie-Caroline Dieu-Nosjean, Koustubh Ranade, Guenter Schmidt, Brandon W. Higgs…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:121

    Published on:

  21. Content type: Short report

    High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations of single-reg...

    Authors: Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang, Wenfeng Fang, Yanfang Guan, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen, Shen Zhao, Qiufan Zheng, Hui Pan, Lanjun Zhang, Hao Long, Haoxian Yang…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:98

    Published on:

  22. Content type: Short report

    The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For...

    Authors: Paolo A. Ascierto, Mariaelena Capone, Antonio M. Grimaldi, Domenico Mallardo, Ester Simeone, Gabriele Madonna, Heinrich Roder, Krista Meyer, Senait Asmellash, Carlos Oliveira, Joanna Roder and Julia Grigorieva

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:91

    Published on:

  23. Content type: Research article

    Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are lacking. High nonsynonymous tumor mutational burde...

    Authors: Biagio Ricciuti, Sasha Kravets, Suzanne E. Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce E. Johnson, Mizuki Nishino, Lynette M. Sholl and Mark M. Awad

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:87

    Published on:

  24. Content type: Research article

    Permanence of front-line management of lung cancer by immunotherapies requires predictive companion diagnostics identifying immune-checkpoints at baseline, challenged by the size and heterogeneity of biopsy sp...

    Authors: Anne Monette, Derek Bergeron, Amira Ben Amor, Liliane Meunier, Christine Caron, Anne-Marie Mes-Masson, Nidhameddine Kchir, Kamel Hamzaoui, Igor Jurisica and Réjean Lapointe

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:86

    Published on:

  25. Content type: Research article

    Intrahepatic cholangiocarcinoma (ICC) is a highly mortal malignancy with limited therapeutic options. Immunotherapies targeting PD-1/PD-L1 pathway represent a promising treatment for ICC. However, PD-L1 expres...

    Authors: Chu-Yu Jing, Yi-Peng Fu, Yong Yi, Mei-Xia Zhang, Su-Su Zheng, Jin-Long Huang, Wei Gan, Xin Xu, Jia-Jia Lin, Juan Zhang, Shuang-Jian Qiu and Bo-Heng Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:77

    Published on:

  26. Content type: Research article

    Immune checkpoint inhibitors (ICIs) demonstrate unprecedented efficacy in multiple malignancies; however, the mechanisms of sensitivity and resistance are poorly understood and predictive biomarkers are scarce...

    Authors: Derek L. Clouthier, Scott C. Lien, S. Y. Cindy Yang, Linh T. Nguyen, Venkata S. K. Manem, Diana Gray, Michael Ryczko, Albiruni R. A. Razak, Jeremy Lewin, Stephanie Lheureux, Ilaria Colombo, Philippe L. Bedard, David Cescon, Anna Spreafico, Marcus O. Butler, Aaron R. Hansen…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:72

    Published on:

  27. Content type: Research article

    The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as ...

    Authors: Amy K. Erbe, Wei Wang, Lakeesha Carmichael, Anna Hoefges, Bartosz Grzywacz, Patrick K. Reville, Erik A. Ranheim, Jacquelyn A. Hank, KyungMann Kim, Songwon Seo, Eneida A. Mendonca, Yiqiang Song, Vaishalee P. Kenkre, Fangxin Hong, Randy D. Gascoyne, Elisabeth Paietta…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:70

    Published on:

  28. Content type: Research article

    Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular imm...

    Authors: Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski and Alfred Zippelius

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:67

    Published on:

  29. Content type: Research article

    Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune c...

    Authors: Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N. Gettinger, Roy S. Herbst, David L. Rimm and Kurt A. Schalper

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:65

    Published on:

  30. Content type: Research article

    Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed.

    Authors: Mirjam Fässler, Stefan Diem, Joanna Mangana, Omar Hasan Ali, Fiamma Berner, David Bomze, Sandra Ring, Rebekka Niederer, Cristina del Carmen Gil Cruz, Christian Ivan Pérez Shibayama, Michal Krolik, Marco Siano, Markus Joerger, Mike Recher, Lorenz Risch, Sabine Güsewell…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:50

    Published on:

  31. Content type: Research article

    Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expressio...

    Authors: Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jacob Hagen, Vincent Giamo, Jonathan Andreas, Felicia L. Lenzo, Wang Yirong, Grace K. Dy, Edwin Yau, Amy Early, Hongbin Chen, Wiam Bshara…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:27

    Published on:

  32. Content type: Research article

    Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.

    Authors: Saori Mishima, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Daisuke Kotani, Yasutoshi Kuboki, Hideaki Bando, Takashi Kojima, Toshihiko Doi, Atsushi Ohtsu, Takayuki Yoshino, Takeshi Kuwata, Akihito Tsuji and Kohei Shitara

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:24

    Published on:

  33. Content type: Research article

    Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imag...

    Authors: Matthew Scarpelli, Christopher Zahm, Scott Perlman, Douglas G. McNeel, Robert Jeraj and Glenn Liu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:23

    Published on:

  34. Content type: Short report

    Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when...

    Authors: Cristina Bagacean, Adrian Tempescul, David Ternant, Anne Banet, Nathalie Douet-Guilbert, Anne Bordron, Boutahar Bendaoud, Hussam Saad, Mihnea Zdrenghea, Christian Berthou, Gilles Paintaud and Yves Renaudineau

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:22

    Published on:

  35. Content type: Research article

    PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies used for PD-...

    Authors: Jeffrey M. Conroy, Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Yirong Wang, Felicia L. Lenzo, Wiam Bshara, Maya Khalil, Grace K. Dy, Katherine G. Madden, Keisuke Shirai, Konstantin Dragnev…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:18

    Published on:

  36. Content type: Research article

    Clinical benefit from checkpoint inhibitors has been associated in a tumor-agnostic manner with two main tumor traits. The first is tumor antigenicity, which is typically measured by tumor mutation burden, mic...

    Authors: Patrick Danaher, Sarah Warren, SuFey Ong, Nathan Elliott, Alessandra Cesano and Sean Ferree

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:15

    Published on:

    The Correction to this article has been published in Journal for ImmunoTherapy of Cancer 2019 7:76

  37. Content type: Research article

    Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the...

    Authors: Christina Jensen, Daniel Hargbøl Madsen, Morten Hansen, Henrik Schmidt, Inge Marie Svane, Morten Asser Karsdal and Nicholas Willumsen

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:152

    Published on:

  38. Content type: Research article

    A high density of tumor-infiltrating CD8+ T cells and CD20+ B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma (HGSC). Howev...

    Authors: Iva Truxova, Lenka Kasikova, Michal Hensler, Petr Skapa, Jan Laco, Ladislav Pecen, Lucie Belicova, Ivan Praznovec, Michael J. Halaska, Tomas Brtnicky, Eva Salkova, Lukas Rob, Roman Kodet, Jeremy Goc, Catherine Sautes-Fridman, Wolf Herman Fridman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:139

    Published on:

  39. Content type: Review

    Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomark...

    Authors: Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif and Ena Wang

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:138

    Published on:

  40. Content type: Research article

    Merkel cell carcinoma (MCC) is an aggressive skin cancer that frequently responds to anti-PD-1 therapy. MCC is associated with sun exposure and, in 80% of cases, Merkel cell polyomavirus (MCPyV). MCPyV-specifi...

    Authors: Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian and Paul Nghiem

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:131

    Published on:

  41. Content type: Research article

    Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lu...

    Authors: Aixa E. Soyano, Bhagirathbhai Dholaria, Julian A. Marin-Acevedo, Nancy Diehl, David Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex Adjei, Keith L. Knutson and Yanyan Lou

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:129

    Published on:

  42. Content type: Research article

    We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified.

    Authors: Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:99

    Published on:

  43. Content type: Research article

    Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk d...

    Authors: Philip Friedlander, Kevin Wood, Karl Wassmann, Alan M. Christenfeld, Nina Bhardwaj and William K. Oh

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:90

    Published on:

  44. Content type: Research article

    Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated with immune checkpoint i...

    Authors: Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò and Paolo Antonio Ascierto

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:74

    Published on:

  45. Content type: Research article

    Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer. Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC, however, eventually these tumors acqui...

    Authors: Priyanka C. Iyer, Ramona Dadu, Maria Gule-Monroe, Naifa L. Busaidy, Renata Ferrarotto, Mouhammed Amir Habra, Mark Zafereo, Michelle D. Williams, G. Brandon Gunn, Horiana Grosu, Heath D. Skinner, Erich M. Sturgis, Neil Gross and Maria E. Cabanillas

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:68

    Published on:

  46. Content type: Research article

    The Tumor Inflammation Signature (TIS) is an investigational use only (IUO) 18-gene signature that measures a pre-existing but suppressed adaptive immune response within tumors. The TIS has been shown to enric...

    Authors: Patrick Danaher, Sarah Warren, Rongze Lu, Josue Samayoa, Amy Sullivan, Irena Pekker, Brett Wallden, Francesco M. Marincola and Alessandra Cesano

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:63

    Published on:

  47. Content type: Research article

    Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive ...

    Authors: Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo, Moachun Qin, Yirong Wang, Felicia L. Lenzo, Angela Omilian, Wiam Bshara, Matthew Zibelman…

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:32

    Published on:

  48. Content type: Research article

    Microsatellite instability (MSI) is now being used as a sole biomarker to guide immunotherapy treatment for men with advanced prostate cancer. Yet current molecular diagnostic tests for MSI have not been evalu...

    Authors: Jennifer A. Hempelmann, Christina M. Lockwood, Eric Q. Konnick, Michael T. Schweizer, Emmanuel S. Antonarakis, Tamara L. Lotan, Bruce Montgomery, Peter S. Nelson, Nola Klemfuss, Stephen J. Salipante and Colin C. Pritchard

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:29

    Published on:

  49. Content type: Research article

    One of today’s greatest hurdles for cancer immunotherapy is the absence of information regarding which tumor antigens are already recognized by patients receiving immunotherapies, and whether those therapies t...

    Authors: Tyler W. Hulett, Shawn M. Jensen, Phillip A. Wilmarth, Ashok P. Reddy, Carmen Ballesteros-Merino, Michael E. Afentoulis, Christopher Dubay, Larry L. David and Bernard A. Fox

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:27

    Published on:

  50. Content type: Research article

    Immuno-oncology and cancer immunotherapies are areas of intense research. The numbers and locations of CD8+ tumor-infiltrating lymphocytes (TILs) are important measures of the immune response to cancer with pr...

    Authors: Keith E. Steele, Tze Heng Tan, René Korn, Karma Dacosta, Charles Brown, Michael Kuziora, Johannes Zimmermann, Brian Laffin, Moritz Widmaier, Lorenz Rognoni, Ruben Cardenes, Katrin Schneider, Anmarie Boutrin, Philip Martin, Jiping Zha and Tobias Wiestler

    Citation: Journal for ImmunoTherapy of Cancer 2018 6:20

    Published on:

Annual Journal Metrics